Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119883 · ClinicalTrials.gov registry record · NA
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT03119883: Completed NA study, sponsored by Mayo Clinic.
NCT03119883 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03119883, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clonal plasma cells in MGUS and MM, respectively. It may also allow researchers better determine the transition from MGUS to MM for the development of potential early diagnostic purposes of preventative strategies.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Uniformly-labeled [13C]glucose
- OTHER 5-Carbon C 13-labeled Glutamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2024-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119883
The ClinicalTrials.gov registry entry for NCT03119883 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT03119883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03119883 about?
NCT03119883 is a clinical study titled "Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma". This clinical trial studies the utilization of glutamine by the bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) compared to multiple myeloma (MM). Results from this study may identify metabolic differences between pre-malignant and malignant clon...
What is the current status of trial NCT03119883?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2017-06-02. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03119883?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Uniformly-labeled [13C]glucose (OTHER), 5-Carbon C 13-labeled Glutamine (OTHER).
Who is sponsoring clinical trial NCT03119883?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.